Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature.

Abstract

Abiraterone, a CYP17 inhibitor, blocks androgen biosynthesis in multiple tissue types. In combination with prednisone, it is approved as a first-line treatment for metastatic castration-resistant prostate cancer. We present a case of rhabdomyolysis associated with abiraterone therapy resulting in acute on chronic kidney injury in a patient with metastatic castration-resistant prostate cancer. Strict monitoring should be employed in patients started on abiraterone who have additional risk factors for developing rhabdomyolysis.

• Authors: Michael Dineen, Elizabeth Hansen, Elizabeth Guancial, Lynn Sievert, Deepak Sahasrabudhe
• Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 24 Issue 4 Pg. 314-318 (Jun 2018) ISSN: 1477-092X [Electronic] England
• PMID: 28355968 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Androstenes
• abiraterone

Topics

• Acute Kidney Injury (chemically induced, complications, diagnosis)
• Aged
• Androstenes (adverse effects)
• Disease Progression
• Fatal Outcome
• Humans
• Male
• Prostatic Neoplasms, Castration-Resistant (complications, drug therapy)
• Rhabdomyolysis (chemically induced, complications, diagnosis)